Takeda considers sale of OTC drug unit to focus on profitable products
Takeda Pharmaceutical Co. is considering selling its over-the-counter medicine unit for around ¥400 billion ($3.7 billion) to focus on developing cancer treatments and other advanced medical-use drugs that can generate higher profitability, a source said Monday. The envisioned sale of Takeda Consumer Healthcare Co. comes ...
Takeda says trial based on blood of recovered virus patients could start in July
Fighting disease with blood from survivors is an ancient strategy that has not been well tested for the novel coronavirus.
Japan's largest drugmaker working to develop virus treatment, Dow Jones reports
Takeda Pharmaceutical Co. is developing an experimental therapy for the novel coronavirus with the goal of making it available in 9 to 18 months, the nation's largest drugmaker said. "We will do all that we can to address the novel coronavirus threat," Dr. Rajeev Venkayya, ...
As COVID-19 spreads, Takeda CEO urges more industry investment in vaccines
The spread of novel coronavirus infections is starting to make one thing clear: More vaccine investment is needed, the CEO of Asia's biggest drugmaker said. "The world has to be more proactive than reactive," Christophe Weber, CEO of Takeda Pharmaceutical Co., said in an interview. Although ...
Takeda's dengue vaccine said effective overall in study but with major limitation
Takeda Pharmaceutical Co.'s experimental dengue vaccine was highly effective at preventing the mosquito-borne disease in a late stage study, but it failed to protect against one type of the virus in people with no prior exposure to dengue. Takeda's vaccine was 80.2 percent effective at ...
Takeda nears deal on sale of Russia, Mideast and Africa assets to private equity firms
Takeda Pharmaceutical Co. is nearing the sale of a portfolio of assets in the Middle East, Africa and Russia to separate buyout firms that could help the drugmaker raise about $1 billion to reduce debt, according to people familiar with the matter. The company is ...
Takeda Pharmaceutical to sell drug assets in emerging markets and Europe, sources say
Takeda Pharmaceutical Co. is close to selling some assets in emerging markets and Western Europe, people familiar with the matter said, in a move that would help the Japanese drugmaker reduce its debt pile. Takeda may announce the sale of over-the-counter and prescription drugs in ...
As its drug firms consider move to Tokyo, does Osaka have a future as a modern city of medicine?
The Doshomachi area of the city of Osaka has been the home and birthplace of many pharmaceutical companies since the Edo Period (1603-1868), including some of the leading drugmakers such as Ono Pharmaceutical Co. Long known as a "town of medicine," Osaka, however, has come ...
Takeda expects net loss in fiscal 2019 due to cost of Shire buyout
Takeda Pharmaceutical Co. said Tuesday its profit declined in the business year ended March and it expects to book a net loss of ¥383 billion in the current year due to costs related to its buyout earlier this year of Irish drugmaker Shire PLC. But ...
Takeda sells dry-eye drug to Novartis for deal valued at up to $5.3 billion
Takeda Pharmaceutical Co. Ltd has agreed to sell its dry eye drug to Swiss drugmaker Novartis AG for $3.4 billion and potential milestone payments of up to $1.9 billion, in the first divestment since its takeover of the U.K.'s Shire. Japan's biggest drugmaker aims to ...
Bypassing U.S. regulators, Takeda takes its dengue shot to the tropics first
A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquito-borne disease that infects nearly 400 million people each year. Takeda Pharmaceutical Co. plans to seek approval for the experimental vaccine first in countries where the virus is endemic, ...
Takeda dengue vaccine meets main goal of trial; detailed results to come
Takeda Pharmaceutical Co. said Tuesday that its experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquito-borne disease, meeting the main goal of the drugmaker's late-stage clinical trial. The company said no significant safety concerns have emerged to ...
